<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863055</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08112</org_study_id>
    <nct_id>NCT02863055</nct_id>
  </id_info>
  <brief_title>Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma</brief_title>
  <acronym>NEMO</acronym>
  <official_title>Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with&#xD;
      unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A:&#xD;
      nintedanib and arm B:placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, double blinded, randomized, two-arm phase II trial aiming&#xD;
      to evaluate nintedanib treatment as switch maintenance in patients with unresectable MPM.&#xD;
&#xD;
      After signing of the informed consent and upon confirmation of all eligibility criteria,&#xD;
      patients will be randomized 1:1 to:&#xD;
&#xD;
        -  Arm A: twice daily nintedanib at a dose of 200 mg until progression or unacceptable&#xD;
           toxicities.&#xD;
&#xD;
        -  Arm B: matched placebo.&#xD;
&#xD;
      Response evaluation will be performed through CT scans every 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 4, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>From randomization until progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>From randomization until progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Response according to modified RECIST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg twice a day per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo match twice a day per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib 200 mg administered twice daily</description>
    <arm_group_label>Nintedanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of unresectable Malignant Pleural Mesothelioma (MPM);&#xD;
&#xD;
          -  Response or Stable disease according to modified RECIST criteria [48] after first line&#xD;
             platinum-pemetrexed chemotherapy for 4-6 cycles;&#xD;
&#xD;
          -  Last platinum chemotherapy dose administered within 60 days (i.e. randomization must&#xD;
             occur within 60 days from the last dose of the last cycle of platinum-pemetrexed&#xD;
             chemotherapy);&#xD;
&#xD;
          -  Age &gt;18 years;&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2;&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks in the opinion of the investigator;&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to start of first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior systemic anticancer therapy including cytotoxic therapy or immune-checkpoint&#xD;
             inhibitor, for MPM, other than first line platinum-based doublet chemotherapy;&#xD;
&#xD;
          -  previous extra-pleural pneumonectomy (other forms of previous surgery eg pleurectomy&#xD;
             are acceptable);&#xD;
&#xD;
          -  previous Vascular Endothelial Growth Factor (VEGF) inhibitors (eg bevacizumab,&#xD;
             sorafenib, etc);&#xD;
&#xD;
          -  treatment with other investigational drugs or treatment in another clinical&#xD;
             interventional trial within the past 4 weeks before start of therapy or concomitantly&#xD;
             with the trial;&#xD;
&#xD;
          -  patients that, in the opinion of the investigator, have reduced performance status by&#xD;
             2 ECOG levels (e.g. PS 0 to 2 or PS 1 to 3) from beginning to completion of 1st line&#xD;
             chemotherapy;&#xD;
&#xD;
          -  radiotherapy (with the exception of palliative radiotherapy) during study or within 4&#xD;
             weeks of start of study drug;&#xD;
&#xD;
          -  known brain metastasis or lepto-meningeal disease. Patients with suspicious&#xD;
             neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain&#xD;
             metastasisNo active brain metastases (e.g. stable for &lt; 4 weeks;, no adequate previous&#xD;
             treatment with radiotherapy;, symptomatic, requiring treatment with anti-convulsants;&#xD;
             dexamethasone therapy will be allowed if administered as stable dose for at least one&#xD;
             month before randomization); patients with suspicious neurological symptoms should&#xD;
             undergo a CT scan/MRI of the brain to assess brain metastasis;&#xD;
&#xD;
          -  leptomeningeal metastases;&#xD;
&#xD;
          -  significant weight loss (&gt; 10 %) within the past 6 weeks prior to treatment in the&#xD;
             present trial;&#xD;
&#xD;
          -  pre-existing clinically significant ascites and/or clinically significant pleural&#xD;
             effusion;&#xD;
&#xD;
          -  active or history of bleeding complications that would prevent anti-angiogenic therapy&#xD;
&#xD;
          -  centrally located tumors with radiographic evidence (CT or MRI) of local invasion of&#xD;
             major blood vessels; typical mediastinal pleural involvement with mesothelioma remains&#xD;
             eligible;&#xD;
&#xD;
          -  clinically active cancer other than mesothelioma within 5 years prior to start of&#xD;
             study treatment;&#xD;
&#xD;
          -  radiographic evidence of cavitatory or necrotic tumors;&#xD;
&#xD;
          -  unstoppable use of therapeutic anticoagulation (except low dose heparin and/or heparin&#xD;
             flush as needed for maintenance of an indwelling intravenous device) or antiplatelet&#xD;
             therapy (except for chronic low-dose therapy with acetylsalicylic acid =325mg per&#xD;
             day);&#xD;
&#xD;
          -  clinically significant cardiovascular diseases (i.e. hypertension not controlled by&#xD;
             medical therapy, unstable angina, history of myocardial infarction within the past 6&#xD;
             months, congestive New York Heart Association (NYHA) II, serious cardiac arrhythmia,&#xD;
             clinically significant pericardial effusion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Popat, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Abdel-Rahman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>08112@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Van Meerbeeck, prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle Surmont, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Luciani, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Chelsea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Kingston</name>
      <address>
        <city>Kingston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Young, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS South Tyneside-South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhona McMenemin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPM</keyword>
  <keyword>Unresectable</keyword>
  <keyword>Phase II</keyword>
  <keyword>Randomized</keyword>
  <keyword>Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

